ERBB2 and breast cancer: A survival analysis of 83 HER2-positive metastatic BC patients found that hormone-negative tumors and larger BMs were related to a poorer prognosis, as well as the use of single-agent chemotherapy with trastuzumab, and the use of only one type of anti-HER2 agent after trastuzumab resulted in a poor prognosis [76].